Dizal Pharmaceutical Hits Day Low at CNY 53.80 Amid Price Pressure

Dizal (Jiangsu) Pharmaceutical Co., Ltd. experienced a notable decline today, with the stock dropping by 5.21% on May 22, 2026. The stock reached an intraday low of CNY 53.80, reflecting a challenging trading environment for the company. In terms of performance metrics, Dizal's one-day performance contrasts sharply with the China Shanghai Composite, which gained 0.87%. Over the past week, the stock has shown a modest increase of 2.33%, but its one-month performance reveals a decline of 5.87%. Year-to-date, Dizal has underperformed with a decrease of 5.28%, while the broader market has seen a positive return of 3.63%. The company's financial health is characterized by a low Return on Capital Employed (ROCE) of 18.72%, indicating limited profitability relative to its capital. Additionally, Dizal's high debt-to-equity ratio raises concerns about its long-term growth potential. With a market capitalization of CNY 24,168 million, the company continues to navigate a complex financial landscape, marked by negative returns on equity and a lack of dividend yield.